Petit T, Georges C, Jung G M, Borel C, Bronner G, Flesch H, Massard G, Velten M, Haegele P, Schraub S
Department of Medical Oncology, Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg, France.
Ann Oncol. 2001 May;12(5):643-6. doi: 10.1023/a:1011191720336.
An attempt was made to improve metachronous oesophageal cancer prognosis through bi-annual systematic esophageal endoscopy screening in patients treated for head and neck cancer.
Bi-annual esophageal endoscopy, without a staining procedure, was performed in 1560 patients from 1987 to 1997. The distribution of previous head and neck cancer was oral cavity (20%), oropharynx (30%), hypopharynx (34%), and larynx (16%). All patients had initial panendoscopic inspection before HNSCC treatment. Esophageal tumors were considered to be second synchronous primaries when discovered within the first six months of initial tumor diagnosis.
Fifty metachronous esophageal asymptomatic cancers (42 T1 and 7 in situ carcinomas) were diagnosed by endoscopy. The median time between the HNC and the esophageal carcinoma was 43 months (7-137 months). Metachronous esophageal carcinoma was discovered in 2.6% of patients with oral cavity tumor, 5.7% of patients with oropharynx tumor, 2.3% of patients with hypopharynx tumor, and 1.7% of patients with larynx tumor. Causes of death were: 41.1% related to esophageal tumor with tumor progression, metastatic evolution, or treatment toxicity; 28.9% related to non malignant causes; 26.6% related to a cancer that was not of esophageal origin.
Over a 10-year period, systematic bi-annual esophageal endoscopy uncovered metachronous esophageal tumors in 3.2% of 1560 patients originally treated for head and neck carcinoma, developing in a median time of 47 months. Patients with initial oropharyngeal tumors had a significantly higher risk of metachronous esophageal SCC, compared to the other tumor sites (P < 0.02 with Fisher exact test). Given the elevated death rate not related to the esophageal cancer and the median survival of 16 months, any potential benefit from this time-consuming procedure is debatable.
尝试通过对头颈部癌患者每半年进行一次系统性食管内镜筛查来改善异时性食管癌的预后。
1987年至1997年期间,对1560例患者进行了每半年一次的食管内镜检查,未采用染色程序。既往头颈部癌的分布情况为:口腔(20%)、口咽(30%)、下咽(34%)和喉(16%)。所有患者在头颈部鳞状细胞癌(HNSCC)治疗前均进行了初始的全内镜检查。食管肿瘤在初始肿瘤诊断后的前六个月内被发现时,被视为第二同步原发肿瘤。
通过内镜诊断出50例异时性食管无症状癌(42例T1期和7例原位癌)。头颈部癌(HNC)与食管癌之间的中位时间为43个月(7 - 137个月)。在口腔肿瘤患者中,2.6%发现了异时性食管癌;口咽肿瘤患者中为5.7%;下咽肿瘤患者中为2.3%;喉肿瘤患者中为1.7%。死亡原因如下:41.1%与食管肿瘤相关,包括肿瘤进展、转移或治疗毒性;28.9%与非恶性原因相关;26.6%与非食管源性癌症相关。
在10年期间,系统性每半年一次的食管内镜检查在1560例最初接受头颈部癌治疗的患者中,发现了3.2%的异时性食管肿瘤,中位发病时间为47个月。与其他肿瘤部位相比,初始口咽肿瘤患者发生异时性食管鳞状细胞癌(SCC)的风险显著更高(Fisher精确检验,P < 0.02)。鉴于与食管癌无关的死亡率升高以及中位生存期为16个月,这种耗时程序的任何潜在益处都值得商榷。